Package Leaflet: Information for the Patient
Paxneury 1 mg prolonged-release tablets
Paxneury 2 mg prolonged-release tablets
Paxneury 3 mg prolonged-release tablets
Paxneury 4 mg prolonged-release tablets
Paxneury 5 mg prolonged-release tablets
Paxneury 6 mg prolonged-release tablets
Paxneury 7 mg prolonged-release tablets
guanfacine
Read the entire package leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the package leaflet
What is Paxneury
Paxneury contains the active substance guanfacine. This medicine belongs to a group of medicines that affect brain activity. This medicine may help improve your attention and concentration and make you less impulsive and hyperactive.
What is Paxneury used for
This medicine is used to treat “attention deficit hyperactivity disorder” (ADHD) in children and adolescents from 6 to 17 years old in whom current stimulant medicines are not appropriate and/or current medicines do not adequately control the symptoms of ADHD.
The medicine is given as part of a treatment program, which usually includes the following:
About ADHD
People with ADHD have problems with:
ADHD can cause problems in everyday life. Children and adolescents with ADHD may have difficulties with learning and with schoolwork. They may find it hard to behave well at home, at school, or in other places.
Do not take Paxneury:
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Paxneury:
Talk to your doctor or pharmacist if you are taking this medicine and:
Paxneury may affect your weight and height if you take it for a long time. Therefore, your doctor will monitor your growth.
Do not stop taking Paxneury without talking to your doctor first. If you stop taking Paxneury suddenly, you may experience withdrawal symptoms such as increased heart rate and high blood pressure (see section 4).
If any of the above applies to you (or if you are not sure), talk to your doctor or pharmacist before taking this medicine. This is because this medicine may make these problems worse. Your doctor will monitor you regularly to see how this medicine affects you.
Children (under 6 years of age) and adults (from 18 years of age)
This medicine must not be used in children under 6 years of age or in adults from 18 years of age because it is not known if it works or if it is safe.
Checks that your doctor will perform when you take Paxneury
Before you start taking this medicine, your doctor will make sure that this medicine is safe for you and that it will help you. While you are taking this medicine, your doctor will repeat these checks every week at the beginning of treatment, after dose adjustments, at least every 3 months during the first year, and at least twice a year thereafter. These checks may include:
You should talk to your doctor if you do not improve or if you get worse and feel very sleepy or drowsy after taking this medicine for about 6 weeks. Your doctor may want to review your treatment.
Other medicines and Paxneury
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Paxneury and some medicines can interact.
In particular, tell your doctor or pharmacist if you are taking any of the following types of medicines:
Medicines | Used to treat |
Aprepitant | Nausea and dizziness |
Atazanavir, efavirenz, etravirine, fosamprenavir, indinavir, nevirapine, ritonavir, saquinavir | HIV infection |
Ciprofloxacin, chloramphenicol, clarithromycin, erythromycin, rifabutin, rifampicin, telithromycin | Bacterial infections |
Fluconazole, itraconazole, posaconazole, ketoconazole | Fungal infections |
Crizotinib, imatinib | Cancer |
Diltiazem, verapamil | Cardiovascular diseases |
Boceprevir, telaprevir | Viral hepatitis |
Suboxone | Substance dependence |
Bosentan | Cardiovascular diseases (e.g., constriction of pulmonary blood vessels) |
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone | Used to control epilepsy |
Modafinil | Medicine that promotes wakefulness and is used to treat sleep disorders |
St. John's Wort | Herbal medicine used to treat depression |
If any of the above applies to you or if you are not sure, talk to your doctor or pharmacist before taking this medicine.
Taking Paxneury with food, drinks, and alcohol
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel dizzy or drowsy when taking this medicine, especially at the start of treatment, and this may last for 2 to 3 weeks or possibly longer. If this happens, do not drive, ride a bike, use tools or machines, or take part in activities that may cause injury until you know how this medicine affects you. Fainting has also been reported, although this is not a common side effect.
Paxneury contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.
Paxneury contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially sodium-free.
Your treatment will start under the supervision of a specialist in child and/or adolescent behavioral disorders.
Follow the instructions for taking this medicine exactly as your doctor or pharmacist has told you. If you are unsure, talk to your doctor or pharmacist.
As part of your treatment, your doctor will closely monitor how Paxneury affects you at the start of treatment and/or during dose adjustments.
How much to take
How to take Paxneury
Duration of treatment
If you need to take Paxneury for more than a year, your doctor will monitor your response to treatment and may interrupt the medicine for a short period; this can be done during school holidays. This break will show if you need to continue taking the medicine.
If you take more Paxneury than you should
If you take more Paxneury than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you and tell them how much you have taken.
The following effects may happen: high or low blood pressure, slow heart rate, slow breathing rate, tiredness or exhaustion.
If you forget to take Paxneury
If you forget a dose, wait until the next day and take your normal dose.
If you stop taking Paxneury
Do not stop taking this medicine without talking to your doctor first.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you are concerned about any of these, talk to your doctor.
If you do not feel well while taking the medicine, talk to an adult straight away. Serious side effects
The following side effects have been reported: drowsiness (sedation), dizziness (hypotension), and slow heart rate (bradycardia), fainting or loss of consciousness (syncope), a serious withdrawal side effect, with high blood pressure after sudden interruption of Paxneury; symptoms may include headaches, feeling confused, nervousness, agitation, and tremors (hypertensive encephalopathy).
Some of these side effects are more likely to happen at the start of treatment and may disappear as treatment continues. If you experience any of these side effects, talk to your doctor straight away.
Other side effects
The following side effects have been reported.
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice any damage to the tablets or the blister.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The other components are hypromellose (2208), methacrylic acid-ethyl acrylate copolymer (type A), lactose monohydrate, povidone, crospovidone (type A), microcrystalline cellulose, anhydrous colloidal silica, sodium lauryl sulfate, polysorbate 80, fumaric acid, glycerol dibehenate.
Product Appearance and Package Contents
Paxneury is a prolonged-release tablet, which means that the active ingredient is released from the tablet over a period of time. The tablets come in packages of:
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí
Barcelona – Spain
Manufacturer
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí
Barcelona – Spain
or
Neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Strasse 23, Richrath
Langenfeld (Rheinland)
40764, Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Neuraxpharm Belgium Tel: +32 (0)2 732 56 95 | Lithuania Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Luxembourg Neuraxpharm France Tel: +32 (0)2 732 56 95 | |
Czech Republic Neuraxpharm Bohemia s.r.o. Tel: +420 739 232 258 | Hungary Neuraxpharm Hungary Kft. Tel: +36 30 464 6834 |
Denmark Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 (Sweden) | Malta Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Germany Neuraxpharm Arzneimittel GmbH Tel: +49 2173 1060 0 | Netherlands Neuraxpharm Netherlands B.V. Tel: +31 70 208 5211 |
Estonia Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 | Norway Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 (Sweden) |
Greece Brain Therapeutics PC Tel: +30 210 993 1458 | Austria Neuraxpharm Austria GmbH Tel: +43 (0) 2236 320038 |
Spain Neuraxpharm Spain, S.L.U. Tel: +34 93 475 96 00 | Poland Neuraxpharm Polska Sp. z.o.o. Tel: +48 783 423 453 |
France Neuraxpharm France Tel: +33 1.53.62.42.90 | Portugal Neuraxpharm Portugal, Unipessoal Lda Tel: +351 910 259 536 |
Croatia Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 602 24 21 | Romania Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 602 24 21 |
Ireland Neuraxpharm Ireland Ltd. Tel: +353 (0)1 428 7777 | Slovenia Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 602 24 21 |
Iceland Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 (Sweden) | Slovakia Neuraxpharm Slovakia a.s. Tel: +421 255 425 562 |
Italy Neuraxpharm Italy S.p.A. Tel: +39 0736 980619 | Finland Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 (Sweden) |
Cyprus Brain Therapeutics ΙΚΕ Tel: +30 210 993 1458 | Sweden Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 |
Latvia Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 | United Kingdom (Northern Ireland) Neuraxpharm Ireland Ltd. Tel: +353 1 428 7777 |
Date of the Last Revision of this Leaflet:
Other Sources of Information
Detailed information about this medication is available on the European Medicines Agency website: https://www.ema.europa.eu.